Date: 2014-12-19
Type of information: Development agreement
Compound: Brinavess™ (vernakalant IV)
Company: Cardiome Pharma (Canada) Eddingpharm (China)
Therapeutic area: Cardiovascular diseases
Type agreement: development commercialisation
Action mechanism:
Disease: conversion of recent onset atrial fibrillation to sinus rhythm in adults
Details: * On December 19, 2014, Cardiome Pharma announced that one of its subsidiaries has entered into an agreement with Eddingpharm to develop and commercialize Brinavess™ in China, Taiwan, and Macau and re-launch Brinavess™ in Hong Kong. Eddingpharm will be responsible for any clinical trials and regulatory approvals required to commercialize Brinavess™ in the countries covered by the agreement. Under the terms of the agreement, Eddingpharm has agreed to an upfront payment of $1.0 million and specific annual commercial goals for Brinavess™. Cardiome is also eligible to receive regulatory milestone payments of up to $3.0 million. Other financial details have not been disclosed
Financial terms:
Latest news:
